Next Generation HIV Vaccines & Therapies

摘要 要求为题为“下一代艾滋病毒疫苗和 治疗，由米歇尔C。作者声明：Robert F.约翰·西利西亚诺Mascola和Margaret E. 阿克曼。会议将于2021年2月21日至25日在新墨西哥州圣达菲举行。 尽管经过多年的研究，成功的HIV-1疫苗或治愈方法仍然是最优先考虑的问题之一 传染病方面未得到满足的需求。因此，本次Keystone研讨会旨在 在艾滋病毒疫苗和/或治愈途径领域工作的科学家们一起。节目 旨在突出这两个领域的最新成果。会议旨在促进合作， 这些新的结果有助于加快进展和治疗方法。本程序中的会话 重点关注疫苗开发的新方法，包括疫苗 免疫学、被动疗法和基因疫苗接种。此外，正在进行的人类疫苗的结果 临床试验也将纳入会议。此外，以治疗艾滋病毒为重点的会议将 解决病毒潜伏期的问题以及如何控制它，并将强调与治疗相关的人类临床 审判会议组织者希望引出和确定未来调查的领域，鼓励新的 伙伴关系，并共同产生设计更好的疫苗，治疗方法， 和网络，这将有助于对预防和治疗这一疾病采取变革性的办法。

ABSTRACT Support is requested for a Keystone Symposia conference entitled Next Generation HIV Vaccines & Therapies, organized by Drs. Michel C. Nussenzweig, Robert F. Siliciano, John R. Mascola and Margaret E. Ackerman. The conference will be held in Santa Fe, New Mexico from February 21-25, 2021. Despite the many years of research, a successful vaccine or cure for HIV-1 remains among the highest priority areas of unmet need in infectious disease. As such, this Keystone Symposia conference was designed to bring together scientists working in the fields of HIV vaccines and/or the pathway to a cure. The program was designed to highlight recent results in both areas. The conference seeks to foster collaborations that will build upon these new results to help accelerate progress and treatment methods. The sessions in this program were developed to include a focus on novel approaches to vaccine development including vaccine immunology, passive therapies, and genetic vaccination. Additionally, results from ongoing human vaccine clinical trials will also be integrated into the conference. Moreover, sessions focused on a cure for HIV will address the problem of viral latency and how it is controlled and will emphasize cure-related human clinical trials. The conference organizers hope to elicit and identify areas of future investigation, encourage new partnerships, and collectively generate the knowledge required to design better vaccines, treatment methods, and networks that will facilitate transformative approaches to prevention and cure for this disease.